Direct-to-consumer (DTC) telemedicine enables any paying patient to obtain medical consultation and treatment via telephone, computer, or smartphone without a prior physician-patient relationship. Direct-to-consumer telemedicine services emerged in the early 2000s and have increased rapidly to several million patient visits annually. 1, 2 Physician concern about exposure to malpractice risk in DTC telemedicine has prompted many services to provide malpractice insurance with employment. 2 Furthermore, researchers and regulators have raised concerns about DTC telemedicine, including substandard verification of patient identity, suboptimal diagnosis and treatment, and inadequate medical history taking, all of which have the potential to result in malpractice litigation. 3 However, the malpractice risk of DTC telemedicine has not been studied.
Methods | We analyzed reported cases of medical malpractice in DTC telemedicine. A reported case is one in which a decision of the court is rendered that includes any judgment, ruling, opinion, dismissal, or other judicial action of the court. From October 1, 2018, to November 1, 2018, we queried the LexisNexis legal case database, which contains all reported cases from federal and state courts. We used 25 queries derived from the terms telemedicine, telehealth, malpractice, direct-to-consumer, DTC, direct-to-patient, internet, online, app, doctor, and physician and the names of 10 large DTC telemedicine services. Reported cases were first reviewed for material relevance to DTC telemedicine, and they were included if the case was brought by or against a DTC telemedicine service or representative, or if the case named a health care professional as a defendant in conjunction with the use of DTC telemedicine. Cases found to be relevant to DTC telemedicine were then reviewed for relevance to medical malpractice and were included if a health care professional or DTC telemedicine service was named as a defendant in a case of medical malpractice. The authors were solely responsible for the database queries, review of cases, and analysis.
Results | We identified 551 reported cases. None involved claims of medical malpractice against DTC telemedicine services or their health care professionals.
Discussion | In this study, no reported cases of medical malpractice related to DTC telemedicine were found. The study was limited by the inability to assess malpractice claims that were not reported, which includes those in process, decided in confidential arbitration, or settled prior to a court decision through mediation or otherwise. Since slightly more than 1 in 4 medical malpractice claims are associated with court decisions, 4 the existence of claims without court decisions is therefore possible and was not accounted for in this study. Several factors may account for the absence of reported cases of malpractice associated with DTC telemedicine. First, conditions amenable to care via DTC telemedicine may be at low risk for malpractice. The largest DTC telemedicine service typically treats "sinus problems, respiratory infections, allergies, and flu symptoms," conditions unlikely to result in malpractice claims and typically managed by physicians in specialties with low malpractice risk. 2, 5 Specialists with high malpractice risk, such as neurosurgeons, are not available via telemedicine, 5 and emergency telemedicine services, such as telestroke, are not available directly to consumers. Alternatively, the generally low-acuity conditions treated by DTC telemedicine may result in malpractice claims that are more likely to be resolved prior to a court decision. Second, DTC telemedicine services often approach care in ways that likely reduce malpractice risk. For example, many DTC teledermatology services treat only acne and do not prescribe medications (eg, isotretinoin) that are associated with higher malpractice risk. 6 Additionally, DTC telemedicine services often have stated policies not to prescribe controlled substances. Direct-to-consumer telemedicine services also provide routine documentation to patients advising them to seek an in-person consultation for any ongoing concerns. This study found no reported cases of medical malpractice in DTC telemedicine. Further research on claimslevel or telemedicine service-level data would provide additional insight. Figure 1 in the article depicts an early and visually striking increase in CVD incidence across blood pressure ranges, with a clear separation of the 4 blood pressure curves after only 5 years. In their unadjusted model, the authors reported a hazard ratio of 6.03 in patients with stage 2 hypertension compared with patients with normal blood pressure. This ratio was reduced to 3.49 in their multivariable model-still a considerable association. We are concerned, however, that the Kaplan-Meier curve showed the graphic results of their unadjusted model, which may overemphasize the contribution of elevated blood pressure to premature CVD incidence. From this figure, the effects of important covariates such as age, sex, race, smoking status, and body mass index on the association with premature CVD cannot be differentiated. This is especially important because hypertension may take years to lead to detectable negative outcomes. We believe a Cox proportional hazards cumulative incidence curve using the multivariable model would be a more accurate visual representation of the demonstrated associations. A similar objection can be made for Figure 2 in the article, which plots the association between blood pressure and all-cause mortality.
In addition to the lack of adjustment for important risk factors, the overall event rates were relatively low, further contributing to the overstatement of the effect of abnormal blood pressure in young adulthood.
In an accompanying Editorial, 2 Dr Vasan referenced Rose's definition of hypertension as "the level of blood pressure at which investigation and management does more good than harm." Similarly, we propose that clinicians caring for young patients with hypertension would be better able to interpret and apply the presented data if the accompanying figures reflected the model that is most likely to approximate the true effect of elevated blood pressure in young adulthood on morbidity and mortality.
In Reply In response to the comments of Dr de Kouchkovsky and colleagues, we estimated the cumulative incidence of CVD events and all-cause mortality using unadjusted Cox regression models ( Figure, A and C) and models that included adjustment for age, sex, race, study site, education level, body mass index, smoking status, physical activity, total cholesterol, high-density lipoprotein cholesterol, and fasting glucose (Figure, B and D) . Consistent with the results in the original article, 1 the cumulative incidence of CVD events and all-cause mortality associated with stage 2 hypertension was lower in the adjusted compared with unadjusted models. However, the cumulative incidence remained 4 times higher among participants with stage 2 hypertension vs their counterparts with normal blood pressure. de Kouchkovsky and colleagues also mention low absolute risk for CVD events associated with elevated blood pressure and stage 1 hypertension. The population was young, and these groups may need to be further risk stratified when choosing in whom to initiate pharmacological therapy in conjunction with lifestyle changes vs lifestyle changes alone. Randomized clinical trials are needed to determine if a treatment benefit can be achieved over a short to moderate time frame in some subgroups of young adults (eg, a high lifetime risk of CVD) with elevated blood pressure or stage 1 hypertension. Studies in young adults evaluating subclinical CVD markers (eg, left ventricular hypertrophy, coronary artery calcium) as outcomes would be an initial step toward providing evidence that pharmacological treatments are appropriate for young adults with hypertension.
